|
March 28, 2003
Medicure, Duke Spotlight MEND-1 Results at the American College of Cardiology
Meetings
WINNIPEG, Manitoba
- (March 28, 2003) - Medicure Inc.
(TSX: MPH), a cardiovascular drug discovery and development company,
is pleased to announce that it will co-host a Satellite Symposium
at the 52nd Annual Scientific Sessions of the American College of
Cardiology in Chicago, Illinois, to announce the positive results
of the recently completed phase II MEND-1 clinical study of its
lead drug, MC-1. The event will
be co-hosted by Duke Clinical Research Institute and will feature
a presentation by Dr. James E. Tcheng, MD, F.A.C.C., Associate Professor
of Medicine, Duke University Medical Center and the Principal Investigator
of the trial.
In addition,
Medicure also will host a Conference Call on Tuesday, April 1, 2003,
to discuss the MEND-1 Phase II clinical study. Participating on
the Conference Call from Medicure's senior management group will
be Dr. Albert D. Friesen, PhD., Chairman and Chief Executive Officer,
and Dr. Karl-Gunnar Hidinger, PhD., Vice-President, Clinical Development.
Also taking part will be Dr. Tcheng, and Dr. David Kandzari, MD,
Director, Interventional Cardiology Research, Duke University Medical
Centre and a sub-investigator on the MEND-1 clinical trial.
A News Release
regarding the MEND-1 clinical trial will be issued in the morning
of March 31, 2003, with the Conference Call taking place at 11 a.m.
Eastern Standard Time the following day.
SUMMARY OF CONFERENCE
CALL
Date of Conference
Call: Tuesday, April 1, 2003
Time of Call:
11 a.m. Eastern Standard Time
Dial-in Numbers
for 1-877-667-7774 (Toll Free)
Participants: 416-695-6120 (Toronto area participants)
About Medicure
Inc.
Medicure Inc. is a cardiovascular
drug discovery and development Company focused on developing effective
therapeutics for unmet needs in the field of cardiovascular medicine
including the prevention and treatment of ischemia, ischemic reperfusion
injury, and stroke.
This press release
contains forward-looking statements that involve risks, which may
cause actual results to differ materially from the statements made,
and accordingly may be deemed to be forward-looking statements made
pursuant to the safe harbor provisions of the Private Securities
Litigation Reform Act of 1995. The forward-looking statements are
made as of the date hereof, and the Company disclaims any intention
and has no obligation or responsibility to update or revise any
forward-looking statements, whether as a result of new information,
future events, or otherwise.
For more information, please contact:
Don Bain
Director of Investor & Public Relations
Medicure Inc.
Tel. 888-435-2220/Fax 204-488-9823
info@medicure.com
Back to 2003 News Archives
|
|
